{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:00:53Z","timestamp":1791874853700,"version":"4.3.4"},"reference-count":176,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s11011-021-00844-y","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T03:32:18Z","timestamp":1635305538000},"page":"1757-1771","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Metabolism in Huntington\u2019s disease: a major contributor to pathology"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3433-0070","authenticated-orcid":false,"given":"Akanksha","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9459-385X","authenticated-orcid":false,"given":"Namita","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"key":"844_CR1","doi-asserted-by":"publisher","first-page":"31411","DOI":"10.1038\/srep31411","volume":"6","author":"K Aditi","year":"2016","unstructured":"Aditi K, Shakarad MN, Agrawal N (2016) Altered lipid metabolism in Drosophila model of Huntington\u2019s disease. Sci Rep 6:31411. https:\/\/doi.org\/10.1038\/srep31411","journal-title":"Sci Rep"},{"key":"844_CR2","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1007\/s00415-019-09263-7","volume":"266","author":"T Aldaz","year":"2019","unstructured":"Aldaz T, Nigro P, S\u00e1nchez-G\u00f3mez A et al (2019) Non-motor symptoms in Huntington\u2019s disease: a comparative study with Parkinson\u2019s disease. J Neurol 266:1340\u20131350. https:\/\/doi.org\/10.1007\/s00415-019-09263-7","journal-title":"J Neurol"},{"key":"844_CR3","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1007\/s00018-019-03051-2","volume":"76","author":"JV Andersen","year":"2019","unstructured":"Andersen JV, Skotte NH, Aldana BI et al (2019) Enhanced cerebral branched-chain amino acid metabolism in R6\/2 mouse model of Huntington\u2019s disease. Cell Mol Life Sci 76:2449\u20132461. https:\/\/doi.org\/10.1007\/s00018-019-03051-2","journal-title":"Cell Mol Life Sci"},{"key":"844_CR4","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1006\/nbdi.2002.0562","volume":"11","author":"OA Andreassen","year":"2002","unstructured":"Andreassen OA, Dedeoglu A, Stanojevic V et al (2002) Huntington\u2019s disease of the endocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression. Neurobiol Dis 11:410\u2013424. https:\/\/doi.org\/10.1006\/nbdi.2002.0562","journal-title":"Neurobiol Dis"},{"key":"844_CR5","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1136\/jnnp.72.6.726","volume":"72","author":"J Andrich","year":"2002","unstructured":"Andrich J, Schmitz T, Saft C et al (2002) Autonomic nervous system function in Huntington\u2019s disease. J Neurol Neurosurg Psychiatry 72:726\u2013731. https:\/\/doi.org\/10.1136\/jnnp.72.6.726","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"844_CR6","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s00702-009-0310-1","volume":"116","author":"JE Andrich","year":"2009","unstructured":"Andrich JE, Wobben M, Klotz P et al (2009) Upper gastrointestinal findings in Huntington\u2019s disease: patients suffer but do not complain. J Neural Transm 116:1607\u20131611. https:\/\/doi.org\/10.1007\/s00702-009-0310-1","journal-title":"J Neural Transm"},{"issue":"Pt 6","key":"844_CR7","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1093\/brain\/119.6.2085","volume":"119","author":"A Antonini","year":"1996","unstructured":"Antonini A, Leenders KL, Spiegel R et al (1996) Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington\u2019s disease. Brain 119(Pt 6):2085\u20132095. https:\/\/doi.org\/10.1093\/brain\/119.6.2085","journal-title":"Brain"},{"key":"844_CR8","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.38744","volume":"7","author":"I Arnoux","year":"2018","unstructured":"Arnoux I, Willam M, Griesche N et al (2018) Metformin reverses early cortical network dysfunction and behavior changes in Huntington\u2019s disease. Elife 7:e38744. https:\/\/doi.org\/10.7554\/eLife.38744","journal-title":"Elife"},{"key":"844_CR9","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1365-2265.2009.03661.x","volume":"73","author":"NA Aziz","year":"2010","unstructured":"Aziz NA, Pijl H, Fr\u00f6lich M et al (2010) Leptin secretion rate increases with higher CAG repeat number in Huntington\u2019s disease patients. Clin Endocrinol 73:206\u2013211. https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03661.x","journal-title":"Clin Endocrinol"},{"key":"844_CR10","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s00418-008-0393-z","volume":"129","author":"K Bacos","year":"2008","unstructured":"Bacos K, Bj\u00f6rkqvist M, Peters\u00e9n A et al (2008) Islet beta-cell area and hormone expression are unaltered in Huntington\u2019s disease. Histochem Cell Biol 129:623\u2013629. https:\/\/doi.org\/10.1007\/s00418-008-0393-z","journal-title":"Histochem Cell Biol"},{"key":"844_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.neuron.2005.06.005","volume":"47","author":"B-I Bae","year":"2005","unstructured":"Bae B-I, Xu H, Igarashi S et al (2005) p53 mediates cellular dysfunction and behavioral abnormalities in Huntington\u2019s disease. Neuron 47:29\u201341. https:\/\/doi.org\/10.1016\/j.neuron.2005.06.005","journal-title":"Neuron"},{"key":"844_CR12","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/j.1468-1331.2008.02173.x","volume":"15","author":"KJ B\u00e4r","year":"2008","unstructured":"B\u00e4r KJ, Boettger MK, Andrich J et al (2008) Cardiovagal modulation upon postural change is altered in Huntington\u2019s disease. Eur J Neurol 15:869\u2013871. https:\/\/doi.org\/10.1111\/j.1468-1331.2008.02173.x","journal-title":"Eur J Neurol"},{"key":"844_CR13","volume-title":"Huntington\u2019s disease","author":"G Bates","year":"2002","unstructured":"Bates G, Harper P, Jones L (2002) Huntington\u2019s disease. Oxford University Press, Oxford"},{"issue":"7","key":"844_CR14","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1111\/ene.13630","volume":"25","author":"E Bellosta Diago","year":"2018","unstructured":"Bellosta Diago E, P\u00e9rez-P\u00e9rez J, Santos Lasaosa S, Viloria Alebesque A, Mart\u00ednez-Horta S, Kulisevsky J, L\u00f3pez Del Val J (2018) Neurocardiovascular pathology in pre-manifest and early-stage Huntington\u2019s disease. Eur J Neurol 25(7):956\u2013962. https:\/\/doi.org\/10.1111\/ene.13630","journal-title":"Eur J Neurol"},{"key":"844_CR15","doi-asserted-by":"publisher","first-page":"11758","DOI":"10.1038\/ncomms11758","volume":"7","author":"A Benraiss","year":"2016","unstructured":"Benraiss A, Wang S, Herrlinger S et al (2016) Human glia can both induce and rescue aspects of disease phenotype in Huntington disease. Nat Commun 7:11758. https:\/\/doi.org\/10.1038\/ncomms11758","journal-title":"Nat Commun"},{"key":"844_CR16","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/ana.410230603","volume":"23","author":"S Berent","year":"1988","unstructured":"Berent S, Giordani B, Lehtinen S et al (1988) Positron emission tomographic scan investigations of Huntington\u2019s disease: cerebral metabolic correlates of cognitive function. Ann Neurol 23:541\u2013546. https:\/\/doi.org\/10.1002\/ana.410230603","journal-title":"Ann Neurol"},{"key":"844_CR17","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1093\/hmg\/ddi053","volume":"14","author":"M Bj\u00f6rkqvist","year":"2005","unstructured":"Bj\u00f6rkqvist M, Fex M, Renstr\u00f6m E et al (2005) The R6\/2 transgenic mouse model of Huntington\u2019s disease develops diabetes due to deficient beta-cell mass and exocytosis. Hum Mol Genet 14:565\u2013574. https:\/\/doi.org\/10.1093\/hmg\/ddi053","journal-title":"Hum Mol Genet"},{"key":"844_CR18","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/j.1365-2826.2009.01898.x","volume":"21","author":"TW Boesgaard","year":"2009","unstructured":"Boesgaard TW, Nielsen TT, Josefsen K et al (2009) Huntington\u2019s disease does not appear to increase the risk of diabetes mellitus. J Neuroendocrinol 21:770\u2013776. https:\/\/doi.org\/10.1111\/j.1365-2826.2009.01898.x","journal-title":"J Neuroendocrinol"},{"key":"844_CR19","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/jcbfm.2014.110","volume":"34","author":"L Boussicault","year":"2014","unstructured":"Boussicault L, H\u00e9rard A-S, Calingasan N et al (2014) Impaired brain energy metabolism in the BACHD mouse model of Huntington\u2019s disease: critical role of astrocyte-neuron interactions. J Cereb Blood Flow Metab 34:1500\u20131510. https:\/\/doi.org\/10.1038\/jcbfm.2014.110","journal-title":"J Cereb Blood Flow Metab"},{"key":"844_CR20","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1089\/ars.2006.8.2061","volume":"8","author":"SE Browne","year":"2006","unstructured":"Browne SE, Beal MF (2006) Oxidative damage in Huntington\u2019s disease pathogenesis. Antioxid Redox Signal 8:2061\u20132073. https:\/\/doi.org\/10.1089\/ars.2006.8.2061","journal-title":"Antioxid Redox Signal"},{"key":"844_CR21","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/ana.410410514","volume":"41","author":"SE Browne","year":"1997","unstructured":"Browne SE, Bowling AC, MacGarvey U et al (1997) Oxidative damage and metabolic dysfunction in Huntington\u2019s disease: selective vulnerability of the basal ganglia. Ann Neurol 41:646\u2013653. https:\/\/doi.org\/10.1002\/ana.410410514","journal-title":"Ann Neurol"},{"key":"844_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3233\/JHD-130083","volume":"3","author":"G Buonincontri","year":"2014","unstructured":"Buonincontri G, Wood NI, Puttick SG et al (2014) Right ventricular dysfunction in the R6\/2 transgenic mouse model of Huntington\u2019s disease is unmasked by dobutamine. J Huntingtons Dis 3:25\u201332. https:\/\/doi.org\/10.3233\/JHD-130083","journal-title":"J Huntingtons Dis"},{"key":"844_CR23","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1007\/s00415-008-0964-x","volume":"255","author":"ME Busse","year":"2008","unstructured":"Busse ME, Hughes G, Wiles CM, Rosser AE (2008) Use of hand-held dynamometry in the evaluation of lower limb muscle strength in people with Huntington\u2019s disease. J Neurol 255:1534\u20131540. https:\/\/doi.org\/10.1007\/s00415-008-0964-x","journal-title":"J Neurol"},{"key":"844_CR24","doi-asserted-by":"publisher","DOI":"10.1042\/AN20090058","volume":"2","author":"C Cepeda","year":"2010","unstructured":"Cepeda C, Cummings DM, Andr\u00e9 VM et al (2010) Genetic mouse models of Huntington\u2019s disease: focus on electrophysiological mechanisms. ASN Neuro 2:e00033. https:\/\/doi.org\/10.1042\/AN20090058","journal-title":"ASN Neuro"},{"key":"844_CR25","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1093\/hmg\/ddp243","volume":"18","author":"RK Chaturvedi","year":"2009","unstructured":"Chaturvedi RK, Adhihetty P, Shukla S et al (2009) Impaired PGC-1alpha function in muscle in Huntington\u2019s disease. Hum Mol Genet 18:3048\u20133065. https:\/\/doi.org\/10.1093\/hmg\/ddp243","journal-title":"Hum Mol Genet"},{"key":"844_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2017.e00381","volume":"3","author":"G Chaves","year":"2017","unstructured":"Chaves G, \u00d6zel RE, Rao NV et al (2017) Metabolic and transcriptomic analysis of Huntington\u2019s disease model reveal changes in intracellular glucose levels and related genes. Heliyon 3:e00381. https:\/\/doi.org\/10.1016\/j.heliyon.2017.e00381","journal-title":"Heliyon"},{"key":"844_CR27","doi-asserted-by":"publisher","first-page":"E962","DOI":"10.3390\/cells8090962","volume":"8","author":"G Chaves","year":"2019","unstructured":"Chaves G, Stanley J, Pourmand N (2019) Mutant Huntingtin affects diabetes and Alzheimer\u2019s markers in human and cell models of Huntington\u2019s disease. Cells 8:E962. https:\/\/doi.org\/10.3390\/cells8090962","journal-title":"Cells"},{"key":"844_CR28","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.bbrc.2007.05.093","volume":"359","author":"C-M Chen","year":"2007","unstructured":"Chen C-M, Wu Y-R, Cheng M-L et al (2007) Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington\u2019s disease patients. Biochem Biophys Res Commun 359:335\u2013340. https:\/\/doi.org\/10.1016\/j.bbrc.2007.05.093","journal-title":"Biochem Biophys Res Commun"},{"key":"844_CR29","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1093\/hmg\/ddl481","volume":"16","author":"M-C Chiang","year":"2007","unstructured":"Chiang M-C, Chen H-M, Lee Y-H et al (2007) Dysregulation of C\/EBPalpha by mutant Huntingtin causes the urea cycle deficiency in Huntington\u2019s disease. Hum Mol Genet 16:483\u2013498. https:\/\/doi.org\/10.1093\/hmg\/ddl481","journal-title":"Hum Mol Genet"},{"key":"844_CR30","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.bbadis.2011.05.006","volume":"1812","author":"M-C Chiang","year":"2011","unstructured":"Chiang M-C, Chern Y, Juo C-G (2011) The dysfunction of hepatic transcriptional factors in mice with Huntington\u2019s disease. Biochim Biophys Acta 1812:1111\u20131120. https:\/\/doi.org\/10.1016\/j.bbadis.2011.05.006","journal-title":"Biochim Biophys Acta"},{"key":"844_CR31","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.celrep.2018.03.117","volume":"23","author":"DD Child","year":"2018","unstructured":"Child DD, Lee JH, Pascua CJ et al (2018) Cardiac mTORC1 dysregulation impacts stress adaptation and survival in Huntington\u2019s disease. Cell Rep 23:1020\u20131033. https:\/\/doi.org\/10.1016\/j.celrep.2018.03.117","journal-title":"Cell Rep"},{"key":"844_CR32","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1093\/hmg\/ddh162","volume":"13","author":"YS Choo","year":"2004","unstructured":"Choo YS, Johnson GVW, MacDonald M et al (2004) Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum Mol Genet 13:1407\u20131420. https:\/\/doi.org\/10.1093\/hmg\/ddh162","journal-title":"Hum Mol Genet"},{"key":"844_CR33","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/mds.23258","volume":"26","author":"A Ciammola","year":"2011","unstructured":"Ciammola A, Sassone J, Sciacco M et al (2011) Low anaerobic threshold and increased skeletal muscle lactate production in subjects with Huntington\u2019s disease. Mov Disord 26:130\u2013137. https:\/\/doi.org\/10.1002\/mds.23258","journal-title":"Mov Disord"},{"key":"844_CR34","doi-asserted-by":"publisher","first-page":"807","DOI":"10.5555\/uri:pii:0022214374901784","volume":"84","author":"MB Davidson","year":"1974","unstructured":"Davidson MB, Green S, Menkes JH (1974) Normal glucose, insulin, and growth hormone responses to oral glucose in Huntington\u2019s disease. J Lab Clin Med 84:807\u2013812. https:\/\/doi.org\/10.5555\/uri:pii:0022214374901784","journal-title":"J Lab Clin Med"},{"key":"844_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.105009","volume":"143","author":"A Di Pardo","year":"2020","unstructured":"Di Pardo A, Pepe G, Capocci L et al (2020) Treatment with K6PC-5, a selective stimulator of SPHK1, ameliorates intestinal homeostasis in an animal model of Huntington\u2019s disease. Neurobiol Dis 143:105009. https:\/\/doi.org\/10.1016\/j.nbd.2020.105009","journal-title":"Neurobiol Dis"},{"key":"844_CR36","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/ajmg.a.38494","volume":"176","author":"AS Dickey","year":"2018","unstructured":"Dickey AS, La Spada AR (2018) Therapy development in Huntington disease: from current strategies to emerging opportunities. Am J Med Genet A 176:842\u2013861. https:\/\/doi.org\/10.1002\/ajmg.a.38494","journal-title":"Am J Med Genet A"},{"key":"844_CR37","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/ng0893-387","volume":"4","author":"M Duyao","year":"1993","unstructured":"Duyao M, Ambrose C, Myers R et al (1993) Trinucleotide repeat length instability and age of onset in Huntington\u2019s disease. Nat Genet 4:387\u2013392. https:\/\/doi.org\/10.1038\/ng0893-387","journal-title":"Nat Genet"},{"key":"844_CR38","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1242\/dmm.002451","volume":"2","author":"DE Ehrnhoefer","year":"2009","unstructured":"Ehrnhoefer DE, Butland SL, Pouladi MA, Hayden MR (2009) Mouse models of Huntington disease: variations on a theme. Dis Model Mech 2:123\u2013129. https:\/\/doi.org\/10.1242\/dmm.002451","journal-title":"Dis Model Mech"},{"key":"844_CR39","doi-asserted-by":"publisher","unstructured":"Elifani F, Amico E, Pepe G, Capocci L, Castaldo S, Rosa P, Montano E, Pollice A, Madonna M, Filosa S, Calogero A, Maglione V, Crispi S, Di Pardo A (2019) Curcumin dietary supplementation ameliorates disease phenotype in an animal model of Huntington\u2019s disease.\u00a0Hum Mol Genet\u00a028(23):4012\u20134021. https:\/\/doi.org\/10.1093\/hmg\/ddz247","DOI":"10.1093\/hmg\/ddz247"},{"key":"844_CR40","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000338464","volume":"78","author":"CT Elfers","year":"2012","unstructured":"Elfers CT, Simmons JH, Roth CL (2012) Glucagon-like peptide-1 agonist exendin-4 leads to reduction of weight and caloric intake in a rat model of hypothalamic obesity. Horm Res Paediatr 78:47\u201353. https:\/\/doi.org\/10.1159\/000338464","journal-title":"Horm Res Paediatr"},{"key":"844_CR41","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1136\/jnnp.2010.209668","volume":"82","author":"MOJ OrthHandley","year":"2011","unstructured":"OrthHandley MOJ, European Huntington\u2019s Disease Network et al (2011) Observing Huntington\u2019s disease: the European Huntington\u2019s disease network\u2019s REGISTRY. J Neurol Neurosurg Psychiatry 82:1409\u20131412. https:\/\/doi.org\/10.1136\/jnnp.2010.209668","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"844_CR42","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/hmg\/10.2.145","volume":"10","author":"JN Fain","year":"2001","unstructured":"Fain JN, Del Mar NA, Meade CA et al (2001) Abnormalities in the functioning of adipocytes from R6\/2 mice that are transgenic for the Huntington\u2019s disease mutation. Hum Mol Genet 10:145\u2013152. https:\/\/doi.org\/10.1093\/hmg\/10.2.145","journal-title":"Hum Mol Genet"},{"key":"844_CR43","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1399-0004.1985.tb00185.x","volume":"27","author":"LA Farrer","year":"1985","unstructured":"Farrer LA (1985) Diabetes mellitus in Huntington disease. Clin Genet 27:62\u201367. https:\/\/doi.org\/10.1111\/j.1399-0004.1985.tb00185.x","journal-title":"Clin Genet"},{"key":"844_CR44","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/ajpa.1330670304","volume":"67","author":"LA Farrer","year":"1985","unstructured":"Farrer LA, Meaney FJ (1985) An anthropometric assessment of Huntington\u2019s disease patients and families. Am J Phys Anthropol 67:185\u2013194. https:\/\/doi.org\/10.1002\/ajpa.1330670304","journal-title":"Am J Phys Anthropol"},{"key":"844_CR45","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.bbadis.2009.04.001","volume":"1792","author":"RJ Ferrante","year":"2009","unstructured":"Ferrante RJ (2009) Mouse models of Huntington\u2019s disease and methodological considerations for therapeutic trials. Biochim Biophys Acta 1792:506\u2013520. https:\/\/doi.org\/10.1016\/j.bbadis.2009.04.001","journal-title":"Biochim Biophys Acta"},{"key":"844_CR46","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1097\/00005053-198910000-00021","volume":"177","author":"SE Folstein","year":"1989","unstructured":"Folstein SE (1989) The psychopathology of Huntington\u2019s disease. J Nerv Ment Dis 177:645","journal-title":"J Nerv Ment Dis"},{"key":"844_CR47","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/27376","volume":"395","author":"JM Friedman","year":"1998","unstructured":"Friedman JM, Halaas JL (1998) Leptin and the regulation of body weight in mammals. Nature 395:763\u2013770. https:\/\/doi.org\/10.1038\/27376","journal-title":"Nature"},{"key":"844_CR48","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1001\/archneur.1992.00530350075022","volume":"49","author":"ST Grafton","year":"1992","unstructured":"Grafton ST, Mazziotta JC, Pahl JJ et al (1992) Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington\u2019s disease. Arch Neurol 49:1161\u20131167. https:\/\/doi.org\/10.1001\/archneur.1992.00530350075022","journal-title":"Arch Neurol"},{"key":"844_CR49","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/ana.410390317","volume":"39","author":"M Gu","year":"1996","unstructured":"Gu M, Gash MT, Mann VM et al (1996) Mitochondrial defect in Huntington\u2019s disease caudate nucleus. Ann Neurol 39:385\u2013389. https:\/\/doi.org\/10.1002\/ana.410390317","journal-title":"Ann Neurol"},{"key":"844_CR50","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1006\/exnr.2000.7626","volume":"169","author":"P Guidetti","year":"2001","unstructured":"Guidetti P, Charles V, Chen EY et al (2001) Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production. Exp Neurol 169:340\u2013350. https:\/\/doi.org\/10.1006\/exnr.2000.7626","journal-title":"Exp Neurol"},{"key":"844_CR51","doi-asserted-by":"publisher","first-page":"20681","DOI":"10.1038\/srep20681","volume":"6","author":"RR Handley","year":"2016","unstructured":"Handley RR, Reid SJ, Patassini S et al (2016) Metabolic disruption identified in the Huntington\u2019s disease transgenic sheep model. Sci Rep 6:20681. https:\/\/doi.org\/10.1038\/srep20681","journal-title":"Sci Rep"},{"key":"844_CR52","doi-asserted-by":"publisher","first-page":"E11293","DOI":"10.1073\/pnas.1711243115","volume":"114","author":"RR Handley","year":"2017","unstructured":"Handley RR, Reid SJ, Brauning R et al (2017) Brain urea increase is an early Huntington\u2019s disease pathogenic event observed in a prodromal transgenic sheep model and HD cases. Proc Natl Acad Sci USA 114:E11293\u2013E11302. https:\/\/doi.org\/10.1073\/pnas.1711243115","journal-title":"Proc Natl Acad Sci USA"},{"key":"844_CR53","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1007\/s00415-014-7350-7","volume":"261","author":"M Herben-Dekker","year":"2014","unstructured":"Herben-Dekker M, van Oostrom JCH, Roos RAC et al (2014) Striatal metabolism and psychomotor speed as predictors of motor onset in Huntington\u2019s disease. J Neurol 261:1387\u20131397. https:\/\/doi.org\/10.1007\/s00415-014-7350-7","journal-title":"J Neurol"},{"key":"844_CR54","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1212\/01.wnl.0000194318.74946.b6","volume":"66","author":"SM Hersch","year":"2006","unstructured":"Hersch SM, Gevorkian S, Marder K et al (2006) Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2\u2019dG. Neurology 66:250\u2013252. https:\/\/doi.org\/10.1212\/01.wnl.0000194318.74946.b6","journal-title":"Neurology"},{"key":"844_CR55","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1212\/WNL.0000000000004209","volume":"89","author":"SM Hersch","year":"2017","unstructured":"Hersch SM, Schifitto G, Oakes D et al (2017) The CREST-E study of creatine for Huntington disease: a randomized controlled trial. Neurology 89:594\u2013601. https:\/\/doi.org\/10.1212\/WNL.0000000000004209","journal-title":"Neurology"},{"key":"844_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179283","volume":"12","author":"D Herv\u00e1s","year":"2017","unstructured":"Herv\u00e1s D, Forn\u00e9s-Ferrer V, G\u00f3mez-Escribano AP et al (2017) Metformin intake associates with better cognitive function in patients with Huntington\u2019s disease. PLoS ONE 12:e0179283. https:\/\/doi.org\/10.1371\/journal.pone.0179283","journal-title":"PLoS ONE"},{"key":"844_CR57","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1080\/10408369991239259","volume":"36","author":"J Himms-Hagen","year":"1999","unstructured":"Himms-Hagen J (1999) Physiological roles of the leptin endocrine system: differences between mice and humans. Crit Rev Clin Lab Sci 36:575\u2013655. https:\/\/doi.org\/10.1080\/10408369991239259","journal-title":"Crit Rev Clin Lab Sci"},{"key":"844_CR58","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/mds.25862","volume":"29","author":"R Hoffmann","year":"2014","unstructured":"Hoffmann R, St\u00fcwe SH, Goetze O et al (2014) Progressive hepatic mitochondrial dysfunction in premanifest Huntington\u2019s disease. Mov Disord 29:831\u2013834. https:\/\/doi.org\/10.1002\/mds.25862","journal-title":"Mov Disord"},{"key":"844_CR59","doi-asserted-by":"publisher","first-page":"863","DOI":"10.3233\/JAD-131847","volume":"40","author":"Y Hu","year":"2014","unstructured":"Hu Y, Liang J, Yu S (2014) High prevalence of diabetes mellitus in a five-generation Chinese family with Huntington\u2019s disease. J Alzheimers Dis 40:863\u2013868. https:\/\/doi.org\/10.3233\/JAD-131847","journal-title":"J Alzheimers Dis"},{"key":"844_CR60","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s00221-005-2357-z","volume":"166","author":"MJ Hunt","year":"2005","unstructured":"Hunt MJ, Morton AJ (2005) Atypical diabetes associated with inclusion formation in the R6\/2 mouse model of Huntington\u2019s disease is not improved by treatment with hypoglycaemic agents. Exp Brain Res 166:220\u2013229. https:\/\/doi.org\/10.1007\/s00221-005-2357-z","journal-title":"Exp Brain Res"},{"key":"844_CR61","first-page":"320","volume":"26","author":"G Huntington","year":"1872","unstructured":"Huntington G (1872) On chorea. Med Surg Rep 26:320\u2013321","journal-title":"Med Surg Rep"},{"key":"844_CR62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029522","volume":"7","author":"ER Dorsey","year":"2012","unstructured":"Huntington Study Group COHORT Investigators, Dorsey ER (2012) Characterization of a large group of individuals with huntington disease and their relatives enrolled in the COHORT study. PLoS ONE 7:e29522. https:\/\/doi.org\/10.1371\/journal.pone.0029522","journal-title":"PLoS ONE"},{"key":"844_CR63","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3233\/JHD-130067","volume":"2","author":"SJ Reid","year":"2013","unstructured":"Huntington\u2019s Disease Sheep Collaborative Research Group, Reid SJ, Patassini S et al (2013) Further molecular characterisation of the OVT73 transgenic sheep model of Huntington\u2019s disease identifies cortical aggregates. J Huntingtons Dis 2:279\u2013295. https:\/\/doi.org\/10.3233\/JHD-130067","journal-title":"J Huntingtons Dis"},{"key":"844_CR64","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1212\/wnl.43.12.2689","volume":"43","author":"BG Jenkins","year":"1993","unstructured":"Jenkins BG, Koroshetz WJ, Beal MF, Rosen BR (1993) Evidence for impairment of energy metabolism in vivo in Huntington\u2019s disease using localized 1H NMR spectroscopy. Neurology 43:2689\u20132695. https:\/\/doi.org\/10.1212\/wnl.43.12.2689","journal-title":"Neurology"},{"key":"844_CR65","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1212\/wnl.50.5.1357","volume":"50","author":"BG Jenkins","year":"1998","unstructured":"Jenkins BG, Rosas HD, Chen YC et al (1998) 1H NMR spectroscopy studies of Huntington\u2019s disease: correlations with CAG repeat numbers. Neurology 50:1357\u20131365. https:\/\/doi.org\/10.1212\/wnl.50.5.1357","journal-title":"Neurology"},{"key":"844_CR66","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1093\/hmg\/ddr541","volume":"21","author":"A Johri","year":"2012","unstructured":"Johri A, Calingasan NY, Hennessey TM et al (2012) Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington\u2019s disease. Hum Mol Genet 21:1124\u20131137. https:\/\/doi.org\/10.1093\/hmg\/ddr541","journal-title":"Hum Mol Genet"},{"key":"844_CR67","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1365-2826.2007.01629.x","volume":"20","author":"K Josefsen","year":"2008","unstructured":"Josefsen K, Nielsen MD, J\u00f8rgensen KH et al (2008) Impaired glucose tolerance in the R6\/1 transgenic mouse model of Huntington\u2019s disease. J Neuroendocrinol 20:165\u2013172. https:\/\/doi.org\/10.1111\/j.1365-2826.2007.01629.x","journal-title":"J Neuroendocrinol"},{"key":"844_CR68","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.nbd.2010.08.009","volume":"40","author":"K Josefsen","year":"2010","unstructured":"Josefsen K, Nielsen SMB, Campos A et al (2010) Reduced gluconeogenesis and lactate clearance in Huntington\u2019s disease. Neurobiol Dis 40:656\u2013662. https:\/\/doi.org\/10.1016\/j.nbd.2010.08.009","journal-title":"Neurobiol Dis"},{"key":"844_CR69","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.yjmcc.2018.12.004","volume":"127","author":"AU Joshi","year":"2019","unstructured":"Joshi AU, Ebert AE, Haileselassie B, Mochly-Rosen D (2019) Drp1\/Fis1-mediated mitochondrial fragmentation leads to lysosomal dysfunction in cardiac models of Huntington\u2019s disease. J Mol Cell Cardiol 127:125\u2013133. https:\/\/doi.org\/10.1016\/j.yjmcc.2018.12.004","journal-title":"J Mol Cell Cardiol"},{"key":"844_CR70","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/febs.14706","volume":"286","author":"JV Joviano-Santos","year":"2019","unstructured":"Joviano-Santos JV, Santos-Miranda A, Botelho AFM et al (2019) Increased oxidative stress and CaMKII activity contribute to electro-mechanical defects in cardiomyocytes from a murine model of Huntington\u2019s disease. FEBS J 286:110\u2013123. https:\/\/doi.org\/10.1111\/febs.14706","journal-title":"FEBS J"},{"key":"844_CR71","doi-asserted-by":"publisher","first-page":"32845","DOI":"10.1074\/jbc.M114.612424","volume":"289","author":"K Kannike","year":"2014","unstructured":"Kannike K, Sepp M, Zuccato C et al (2014) Forkhead transcription factor FOXO3a levels are increased in Huntington disease because of overactivated positive autofeedback loop. J Biol Chem 289:32845\u201332857. https:\/\/doi.org\/10.1074\/jbc.M114.612424","journal-title":"J Biol Chem"},{"key":"844_CR72","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1136\/jnnp.39.3.244","volume":"39","author":"HJ Keogh","year":"1976","unstructured":"Keogh HJ, Johnson RH, Nanda RN, Sulaiman WR (1976) Altered growth hormone release in Huntington\u2019s chorea. J Neurol Neurosurg Psychiatry 39:244\u2013248. https:\/\/doi.org\/10.1136\/jnnp.39.3.244","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"844_CR73","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/j.1468-1331.2004.00894.x","volume":"11","author":"J Kobal","year":"2004","unstructured":"Kobal J, Meglic B, Mesec A, Peterlin B (2004) Early sympathetic hyperactivity in Huntington\u2019s disease. Eur J Neurol 11:842\u2013848. https:\/\/doi.org\/10.1111\/j.1468-1331.2004.00894.x","journal-title":"Eur J Neurol"},{"key":"844_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2018.09.001","volume":"135","author":"G Kong","year":"2020","unstructured":"Kong G, Cao K-AL, Judd LM et al (2020) Microbiome profiling reveals gut dysbiosis in a transgenic mouse model of Huntington\u2019s disease. Neurobiol Dis 135:104268. https:\/\/doi.org\/10.1016\/j.nbd.2018.09.001","journal-title":"Neurobiol Dis"},{"key":"844_CR75","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/ana.410410206","volume":"41","author":"WJ Koroshetz","year":"1997","unstructured":"Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF (1997) Energy metabolism defects in Huntington\u2019s disease and effects of coenzyme Q10. Ann Neurol 41:160\u2013165. https:\/\/doi.org\/10.1002\/ana.410410206","journal-title":"Ann Neurol"},{"key":"844_CR76","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1002\/mds.21550","volume":"22","author":"CM Kosinski","year":"2007","unstructured":"Kosinski CM, Schlangen C, Gellerich FN et al (2007) Myopathy as a first symptom of Huntington\u2019s disease in a Marathon runner. Mov Disord 22:1637\u20131640. https:\/\/doi.org\/10.1002\/mds.21550","journal-title":"Mov Disord"},{"key":"844_CR77","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/0022-510x(89)90120-2","volume":"90","author":"HP Kremer","year":"1989","unstructured":"Kremer HP, Roos RA, Fr\u00f6lich M et al (1989) Endocrine functions in Huntington\u2019s disease. A two-and-a-half years follow-up study. J Neurol Sci 90:335\u2013344. https:\/\/doi.org\/10.1016\/0022-510x(89)90120-2","journal-title":"J Neurol Sci"},{"key":"844_CR78","first-page":"199","volume":"63","author":"DE Kuhl","year":"1985","unstructured":"Kuhl DE, Markham CH, Metter EJ et al (1985) Local cerebral glucose utilization in symptomatic and presymptomatic Huntington\u2019s disease. Res Publ Assoc Res Nerv Ment Dis 63:199\u2013209","journal-title":"Res Publ Assoc Res Nerv Ment Dis"},{"issue":"Pt 5","key":"844_CR79","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1093\/brain\/113.5.1405","volume":"113","author":"T Kuwert","year":"1990","unstructured":"Kuwert T, Lange HW, Langen KJ et al (1990) Cortical and subcortical glucose consumption measured by PET in patients with Huntington\u2019s disease. Brain 113(Pt 5):1405\u20131423. https:\/\/doi.org\/10.1093\/brain\/113.5.1405","journal-title":"Brain"},{"key":"844_CR80","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/BF00870669","volume":"241","author":"T Kuwert","year":"1993","unstructured":"Kuwert T, Lange HW, Boecker H et al (1993) Striatal glucose consumption in chorea-free subjects at risk of Huntington\u2019s disease. J Neurol 241:31\u201336. https:\/\/doi.org\/10.1007\/BF00870669","journal-title":"J Neurol"},{"key":"844_CR81","doi-asserted-by":"publisher","first-page":"10127","DOI":"10.1038\/s41598-019-46470-8","volume":"9","author":"P Lakra","year":"2019","unstructured":"Lakra P, Aditi K, Agrawal N (2019) Peripheral expression of mutant huntingtin is a critical determinant of weight loss and metabolic disturbances in Huntington\u2019s disease. Sci Rep 9:10127. https:\/\/doi.org\/10.1038\/s41598-019-46470-8","journal-title":"Sci Rep"},{"key":"844_CR82","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1001\/archneur.65.4.476","volume":"65","author":"NM Lali\u0107","year":"2008","unstructured":"Lali\u0107 NM, Mari\u0107 J, Svetel M et al (2008) Glucose homeostasis in Huntington disease: abnormalities in insulin sensitivity and early-phase insulin secretion. Arch Neurol 65:476\u2013480. https:\/\/doi.org\/10.1001\/archneur.65.4.476","journal-title":"Arch Neurol"},{"key":"844_CR83","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1212\/wnl.38.5.769","volume":"38","author":"DJ Lanska","year":"1988","unstructured":"Lanska DJ, Lavine L, Lanska MJ, Schoenberg BS (1988) Huntington\u2019s disease mortality in the United States. Neurology 38:769\u2013772. https:\/\/doi.org\/10.1212\/wnl.38.5.769","journal-title":"Neurology"},{"key":"844_CR84","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1093\/brain\/awn212","volume":"131","author":"V Leoni","year":"2008","unstructured":"Leoni V, Mariotti C, Tabrizi SJ et al (2008) Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington\u2019s disease. Brain 131:2851\u20132859. https:\/\/doi.org\/10.1093\/brain\/awn212","journal-title":"Brain"},{"key":"844_CR85","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.nbd.2013.03.013","volume":"55","author":"V Leoni","year":"2013","unstructured":"Leoni V, Long JD, Mills JA et al (2013) Plasma 24S-hydroxycholesterol correlation with markers of Huntington disease progression. Neurobiol Dis 55:37\u201343. https:\/\/doi.org\/10.1016\/j.nbd.2013.03.013","journal-title":"Neurobiol Dis"},{"key":"844_CR86","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.cell.2004.09.013","volume":"119","author":"J Lin","year":"2004","unstructured":"Lin J, Wu P-H, Tarr PT et al (2004) Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 119:121\u2013135. https:\/\/doi.org\/10.1016\/j.cell.2004.09.013","journal-title":"Cell"},{"key":"844_CR87","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.cmet.2005.05.004","volume":"1","author":"J Lin","year":"2005","unstructured":"Lin J, Handschin C, Spiegelman BM (2005) Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab 1:361\u2013370. https:\/\/doi.org\/10.1016\/j.cmet.2005.05.004","journal-title":"Cell Metab"},{"key":"844_CR88","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/1531-8249(200007)48:1<72::AID-ANA11>3.0.CO;2-I","volume":"48","author":"R Lodi","year":"2000","unstructured":"Lodi R, Schapira AH, Manners D et al (2000) Abnormal in vivo skeletal muscle energy metabolism in Huntington\u2019s disease and dentatorubropallidoluysian atrophy. Ann Neurol 48:72\u201376","journal-title":"Ann Neurol"},{"key":"844_CR89","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1093\/hmg\/11.17.1911","volume":"11","author":"R Luthi-Carter","year":"2002","unstructured":"Luthi-Carter R, Hanson SA, Strand AD et al (2002) Dysregulation of gene expression in the R6\/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum Mol Genet 11:1911\u20131926. https:\/\/doi.org\/10.1093\/hmg\/11.17.1911","journal-title":"Hum Mol Genet"},{"key":"844_CR90","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.neulet.2006.10.039","volume":"411","author":"TC Ma","year":"2007","unstructured":"Ma TC, Buescher JL, Oatis B et al (2007) Metformin therapy in a transgenic mouse model of Huntington\u2019s disease. Neurosci Lett 411:98\u2013103. https:\/\/doi.org\/10.1016\/j.neulet.2006.10.039","journal-title":"Neurosci Lett"},{"key":"844_CR91","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-e","volume":"72","author":"ME MacDonald","year":"1993","unstructured":"MacDonald ME et al (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. The Huntington\u2019s Disease Collaborative Research Group. Cell 72:971\u2013983. https:\/\/doi.org\/10.1016\/0092-8674(93)90585-e","journal-title":"Cell"},{"key":"844_CR92","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1002\/bies.20029","volume":"26","author":"JL Marsh","year":"2004","unstructured":"Marsh JL, Thompson LM (2004) Can flies help humans treat neurodegenerative diseases? BioEssays 26:485\u2013496. https:\/\/doi.org\/10.1002\/bies.20029","journal-title":"BioEssays"},{"key":"844_CR93","doi-asserted-by":"publisher","first-page":"7431","DOI":"10.1074\/jbc.R800065200","volume":"284","author":"JL Marsh","year":"2009","unstructured":"Marsh JL, Lukacsovich T, Thompson LM (2009) Animal models of polyglutamine diseases and therapeutic approaches. J Biol Chem 284:7431\u20137435. https:\/\/doi.org\/10.1074\/jbc.R800065200","journal-title":"J Biol Chem"},{"key":"844_CR94","doi-asserted-by":"publisher","first-page":"318","DOI":"10.2337\/db08-0799","volume":"58","author":"B Martin","year":"2009","unstructured":"Martin B, Golden E, Carlson OD et al (2009) Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington\u2019s disease. Diabetes 58:318\u2013328. https:\/\/doi.org\/10.2337\/db08-0799","journal-title":"Diabetes"},{"key":"844_CR95","doi-asserted-by":"publisher","first-page":"31766","DOI":"10.1074\/jbc.M112.387316","volume":"287","author":"B Martin","year":"2012","unstructured":"Martin B, Chadwick W, Cong W et al (2012) Euglycemic agent-mediated hypothalamic transcriptomic manipulation in the N171\u201382Q model of Huntington disease is related to their physiological efficacy. J Biol Chem 287:31766\u201331782. https:\/\/doi.org\/10.1074\/jbc.M112.387316","journal-title":"J Biol Chem"},{"key":"844_CR96","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.biopsych.2017.10.019","volume":"83","author":"P McColgan","year":"2018","unstructured":"McColgan P, Gregory S, Seunarine KK et al (2018) Brain regions showing white matter loss in Huntington\u2019s disease are enriched for synaptic and metabolic genes. Biol Psychiatry 83:456\u2013465. https:\/\/doi.org\/10.1016\/j.biopsych.2017.10.019","journal-title":"Biol Psychiatry"},{"key":"844_CR97","doi-asserted-by":"publisher","DOI":"10.1371\/currents.hd.858b4cc7f235df068387e9c20c436a79","author":"AC McCourt","year":"2015","unstructured":"McCourt AC, O\u2019Donovan KL, Ekblad E et al (2015) Characterization of gastric mucosa biopsies reveals alterations in Huntington\u2019s disease. PLoS Curr. https:\/\/doi.org\/10.1371\/currents.hd.858b4cc7f235df068387e9c20c436a79","journal-title":"PLoS Curr"},{"key":"844_CR98","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159870","volume":"11","author":"AC McCourt","year":"2016","unstructured":"McCourt AC, Jakobsson L, Larsson S et al (2016) White adipose tissue browning in the R6\/2 mouse model of Huntington\u2019s disease. PLoS ONE 11:e0159870. https:\/\/doi.org\/10.1371\/journal.pone.0159870","journal-title":"PLoS ONE"},{"key":"844_CR99","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1212\/WNL.0000000000003478","volume":"88","author":"A McGarry","year":"2017","unstructured":"McGarry A, McDermott M, Kieburtz K et al (2017) A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology 88:152\u2013159. https:\/\/doi.org\/10.1212\/WNL.0000000000003478","journal-title":"Neurology"},{"key":"844_CR100","doi-asserted-by":"publisher","DOI":"10.1080\/21675511.2015.1058464","volume":"3","author":"M Mielcarek","year":"2015","unstructured":"Mielcarek M (2015) Huntington\u2019s disease is a multi-system disorder. Rare Dis 3:e1058464. https:\/\/doi.org\/10.1080\/21675511.2015.1058464","journal-title":"Rare Dis"},{"key":"844_CR101","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1004550","volume":"10","author":"M Mielcarek","year":"2014","unstructured":"Mielcarek M, Inuabasi L, Bondulich MK et al (2014) Dysfunction of the CNS-heart axis in mouse models of Huntington\u2019s disease. PLoS Genet 10:e1004550. https:\/\/doi.org\/10.1371\/journal.pgen.1004550","journal-title":"PLoS Genet"},{"key":"844_CR102","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1005021","volume":"11","author":"M Mielcarek","year":"2015","unstructured":"Mielcarek M, Toczek M, Smeets CJLM et al (2015) HDAC4-myogenin axis as an important marker of HD-related skeletal muscle atrophy. PLoS Genet 11:e1005021. https:\/\/doi.org\/10.1371\/journal.pgen.1005021","journal-title":"PLoS Genet"},{"key":"844_CR103","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3389\/fphys.2017.00127","volume":"8","author":"M Mielcarek","year":"2017","unstructured":"Mielcarek M, Smolenski RT, Isalan M (2017) Transcriptional signature of an altered purine metabolism in the skeletal muscle of a Huntington\u2019s disease mouse model. Front Physiol 8:127. https:\/\/doi.org\/10.3389\/fphys.2017.00127","journal-title":"Front Physiol"},{"key":"844_CR104","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.nbd.2006.09.016","volume":"25","author":"MJ Mihm","year":"2007","unstructured":"Mihm MJ, Amann DM, Schanbacher BL et al (2007) Cardiac dysfunction in the R6\/2 mouse model of Huntington\u2019s disease. Neurobiol Dis 25:297\u2013308. https:\/\/doi.org\/10.1016\/j.nbd.2006.09.016","journal-title":"Neurobiol Dis"},{"key":"844_CR105","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1172\/JCI45691","volume":"121","author":"F Mochel","year":"2011","unstructured":"Mochel F, Haller RG (2011) Energy deficit in Huntington disease: why it matters. J Clin Investig 121:493\u2013499. https:\/\/doi.org\/10.1172\/JCI45691","journal-title":"J Clin Investig"},{"key":"844_CR106","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0000647","volume":"2","author":"F Mochel","year":"2007","unstructured":"Mochel F, Charles P, Seguin F et al (2007) Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. PLoS ONE 2:e647. https:\/\/doi.org\/10.1371\/journal.pone.0000647","journal-title":"PLoS ONE"},{"key":"844_CR107","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008025","author":"HGDB MoffittMcPhailWoodman","year":"2009","unstructured":"MoffittMcPhailWoodman HGDB et al (2009) Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington\u2019s disease. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0008025","journal-title":"PLoS ONE"},{"key":"844_CR108","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3233\/JHD-170253","volume":"6","author":"MT Montojo","year":"2017","unstructured":"Montojo MT, Aganzo M, Gonz\u00e1lez N (2017) Huntington\u2019s disease and diabetes: chronological sequence of its association. J Huntingtons Dis 6:179\u2013188. https:\/\/doi.org\/10.3233\/JHD-170253","journal-title":"J Huntingtons Dis"},{"key":"844_CR109","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/ajcn\/50.1.145","volume":"50","author":"LM Morales","year":"1989","unstructured":"Morales LM, Est\u00e9vez J, Su\u00e1rez H et al (1989) Nutritional evaluation of Huntington disease patients. Am J Clin Nutr 50:145\u2013150. https:\/\/doi.org\/10.1093\/ajcn\/50.1.145","journal-title":"Am J Clin Nutr"},{"key":"844_CR110","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/978-1-4939-7825-0_12","volume":"1780","author":"AJ Morton","year":"2018","unstructured":"Morton AJ (2018) Large-brained animal models of Huntington\u2019s disease: sheep. Methods Mol Biol 1780:221\u2013239. https:\/\/doi.org\/10.1007\/978-1-4939-7825-0_12","journal-title":"Methods Mol Biol"},{"key":"844_CR111","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1001\/archneur.1991.00530200036015","volume":"48","author":"RH Myers","year":"1991","unstructured":"Myers RH, Sax DS, Koroshetz WJ et al (1991) Factors associated with slow progression in Huntington\u2019s disease. Arch Neurol 48:800\u2013804. https:\/\/doi.org\/10.1001\/archneur.1991.00530200036015","journal-title":"Arch Neurol"},{"key":"844_CR112","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0146480","volume":"11","author":"R Nambron","year":"2016","unstructured":"Nambron R, Silajd\u017ei\u0107 E, Kalliolia E et al (2016) A metabolic study of Huntington\u2019s disease. PLoS ONE 11:e0146480. https:\/\/doi.org\/10.1371\/journal.pone.0146480","journal-title":"PLoS ONE"},{"key":"844_CR113","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1093\/brain\/awv214","volume":"138","author":"F Niccolini","year":"2015","unstructured":"Niccolini F, Haider S, Reis Marques T et al (2015) Altered PDE10A expression detectable early before symptomatic onset in Huntington\u2019s disease. Brain 138:3016\u20133029. https:\/\/doi.org\/10.1093\/brain\/awv214","journal-title":"Brain"},{"key":"844_CR114","doi-asserted-by":"publisher","DOI":"10.1371\/currents.hd.019b33aae1c519e6e8b68e7cf3e7818e","author":"SMB Nielsen","year":"2015","unstructured":"Nielsen SMB, Hasholt L, N\u00f8rrem\u00f8lle A, Josefsen K (2015) Progressive impairment of lactate-based gluconeogenesis in the Huntington\u2019s disease mouse model R6\/2. PLoS Curr. https:\/\/doi.org\/10.1371\/currents.hd.019b33aae1c519e6e8b68e7cf3e7818e","journal-title":"PLoS Curr"},{"key":"844_CR115","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.jns.2016.02.018","volume":"362","author":"SMB Nielsen","year":"2016","unstructured":"Nielsen SMB, Vinther-Jensen T, Nielsen JE et al (2016) Liver function in Huntington\u2019s disease assessed by blood biochemical analyses in a clinical setting. J Neurol Sci 362:326\u2013332. https:\/\/doi.org\/10.1016\/j.jns.2016.02.018","journal-title":"J Neurol Sci"},{"key":"844_CR116","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nn884","volume":"5","author":"AV Panov","year":"2002","unstructured":"Panov AV, Gutekunst C-A, Leavitt BR et al (2002) Early mitochondrial calcium defects in Huntington\u2019s disease are a direct effect of polyglutamines. Nat Neurosci 5:731\u2013736. https:\/\/doi.org\/10.1038\/nn884","journal-title":"Nat Neurosci"},{"key":"844_CR117","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.bbadis.2016.06.002","volume":"1862","author":"S Patassini","year":"2016","unstructured":"Patassini S, Begley P, Xu J et al (2016) Metabolite mapping reveals severe widespread perturbation of multiple metabolic processes in Huntington\u2019s disease human brain. Biochim Biophys Acta 1862:1650\u20131662. https:\/\/doi.org\/10.1016\/j.bbadis.2016.06.002","journal-title":"Biochim Biophys Acta"},{"key":"844_CR118","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/jnnp.2007.128728","volume":"79","author":"JS Paulsen","year":"2008","unstructured":"Paulsen JS, Langbehn DR, Stout JC et al (2008) Detection of Huntington\u2019s disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 79:874\u2013880. https:\/\/doi.org\/10.1136\/jnnp.2007.128728","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"844_CR119","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1111\/j.1460-9568.2006.04985.x","volume":"24","author":"A Peters\u00e9n","year":"2006","unstructured":"Peters\u00e9n A, Bj\u00f6rkqvist M (2006) Hypothalamic-endocrine aspects in Huntington\u2019s disease. Eur J Neurosci 24:961\u2013967. https:\/\/doi.org\/10.1111\/j.1460-9568.2006.04985.x","journal-title":"Eur J Neurosci"},{"key":"844_CR120","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1093\/hmg\/ddn428","volume":"18","author":"J Phan","year":"2009","unstructured":"Phan J, Hickey MA, Zhang P et al (2009) Adipose tissue dysfunction tracks disease progression in two Huntington\u2019s disease mouse models. Hum Mol Genet 18:1006\u20131016. https:\/\/doi.org\/10.1093\/hmg\/ddn428","journal-title":"Hum Mol Genet"},{"key":"844_CR121","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000212174","volume":"23","author":"S Podolsky","year":"1977","unstructured":"Podolsky S, Leopold NA (1977) Abnormal glucose tolerance and arginine tolerance tests in Huntington\u2019s disease. Gerontology 23:55\u201363. https:\/\/doi.org\/10.1159\/000212174","journal-title":"Gerontology"},{"key":"844_CR122","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/s0140-6736(72)91092-6","volume":"1","author":"S Podolsky","year":"1972","unstructured":"Podolsky S, Leopold NA, Sax DS (1972) Increased frequency of diabetes mellitus in patients with Huntington\u2019s chorea. Lancet 1:1356\u20131358. https:\/\/doi.org\/10.1016\/s0140-6736(72)91092-6","journal-title":"Lancet"},{"key":"844_CR123","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.cmet.2019.03.004","volume":"29","author":"AA Polyzos","year":"2019","unstructured":"Polyzos AA, Lee DY, Datta R et al (2019) Metabolic reprogramming in astrocytes distinguishes region-specific neuronal susceptibility in Huntington mice. Cell Metab 29:1258-1273.e11. https:\/\/doi.org\/10.1016\/j.cmet.2019.03.004","journal-title":"Cell Metab"},{"key":"844_CR124","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1530\/eje.0.1510451","volume":"151","author":"V Popovic","year":"2004","unstructured":"Popovic V, Svetel M, Djurovic M et al (2004) Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington\u2019s disease. Eur J Endocrinol 151:451\u2013455. https:\/\/doi.org\/10.1530\/eje.0.1510451","journal-title":"Eur J Endocrinol"},{"key":"844_CR125","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2217\/fnl-2017-0035","volume":"13","author":"KT Potkin","year":"2018","unstructured":"Potkin KT, Potkin SG (2018) New directions in therapeutics for Huntington disease. Future Neurol 13:101\u2013121. https:\/\/doi.org\/10.2217\/fnl-2017-0035","journal-title":"Future Neurol"},{"key":"844_CR126","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/B978-0-12-381328-2.00014-6","volume":"98","author":"A Reiner","year":"2011","unstructured":"Reiner A, Dragatsis I, Dietrich P (2011) Genetics and neuropathology of Huntington\u2019s disease. Int Rev Neurobiol 98:325\u2013372. https:\/\/doi.org\/10.1016\/B978-0-12-381328-2.00014-6","journal-title":"Int Rev Neurobiol"},{"key":"844_CR127","doi-asserted-by":"publisher","first-page":"dmm038737","DOI":"10.1242\/dmm.038737","volume":"12","author":"M Rodinova","year":"2019","unstructured":"Rodinova M, Krizova J, Stufkova H et al (2019) Deterioration of mitochondrial bioenergetics and ultrastructure impairment in skeletal muscle of a transgenic minipig model in the early stages of Huntington\u2019s disease. Dis Model Mech 12:dmm038737. https:\/\/doi.org\/10.1242\/dmm.038737","journal-title":"Dis Model Mech"},{"key":"844_CR128","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3233\/JHD-199003","volume":"8","author":"FB Rodrigues","year":"2019","unstructured":"Rodrigues FB, Ferreira JJ, Wild EJ (2019) Huntington\u2019s disease clinical trials corner: June 2019. J Huntingtons Dis 8:363\u2013371. https:\/\/doi.org\/10.3233\/JHD-199003","journal-title":"J Huntingtons Dis"},{"key":"844_CR129","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1750-1172-5-40","volume":"5","author":"RAC Roos","year":"2010","unstructured":"Roos RAC (2010) Huntington\u2019s disease: a clinical review. Orphanet J Rare Dis 5:40. https:\/\/doi.org\/10.1186\/1750-1172-5-40","journal-title":"Orphanet J Rare Dis"},{"key":"844_CR130","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1212\/01.wnl.0000065888.88988.6e","volume":"60","author":"HD Rosas","year":"2003","unstructured":"Rosas HD, Koroshetz WJ, Chen YI et al (2003) Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 60:1615\u20131620. https:\/\/doi.org\/10.1212\/01.wnl.0000065888.88988.6e","journal-title":"Neurology"},{"key":"844_CR131","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/ajmg.1400","volume":"105","author":"A Rosenblatt","year":"2001","unstructured":"Rosenblatt A, Brinkman RR, Liang KY et al (2001) Familial influence on age of onset among siblings with Huntington disease. Am J Med Genet 105:399\u2013403","journal-title":"Am J Med Genet"},{"issue":"12","key":"844_CR132","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1001\/jamaneurol.2014.1954","volume":"71","author":"DS Russell","year":"2014","unstructured":"Russell DS, Barret O, Jennings DL, Friedman JH, Tamagnan GD, Thomae D, Alagille D, Morley TJ, Papin C, Papapetropoulos S, Waterhouse RN, Seibyl JP, Marek KL (2014) The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease. JAMA Neurol 71(12):1520\u20131528. https:\/\/doi.org\/10.1001\/jamaneurol.2014.1954","journal-title":"JAMA Neurol"},{"key":"844_CR133","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3233\/JHD-130078","volume":"2","author":"CV Russo","year":"2013","unstructured":"Russo CV, Salvatore E, Sacc\u00e0 F et al (2013) Insulin sensitivity and early-phase insulin secretion in normoglycemic Huntington\u2019s disease patients. J Huntingtons Dis 2:501\u2013507. https:\/\/doi.org\/10.3233\/JHD-130078","journal-title":"J Huntingtons Dis"},{"key":"844_CR134","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004962","volume":"4","author":"N Saleh","year":"2009","unstructured":"Saleh N, Moutereau S, Durr A et al (2009) Neuroendocrine disturbances in Huntington\u2019s disease. PLoS ONE 4:e4962. https:\/\/doi.org\/10.1371\/journal.pone.0004962","journal-title":"PLoS ONE"},{"key":"844_CR135","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162890","volume":"11","author":"L Salem","year":"2016","unstructured":"Salem L, Saleh N, D\u00e9sam\u00e9ricq G et al (2016) Insulin-like growth factor-1 but not insulin predicts cognitive decline in Huntington\u2019s disease. PLoS ONE 11:e0162890. https:\/\/doi.org\/10.1371\/journal.pone.0162890","journal-title":"PLoS ONE"},{"key":"844_CR136","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.expneurol.2009.05.012","volume":"219","author":"J Sassone","year":"2009","unstructured":"Sassone J, Colciago C, Cislaghi G et al (2009) Huntington\u2019s disease: the current state of research with peripheral tissues. Exp Neurol 219:385\u2013397. https:\/\/doi.org\/10.1016\/j.expneurol.2009.05.012","journal-title":"Exp Neurol"},{"key":"844_CR137","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/hmg\/8.5.813","volume":"8","author":"K Sathasivam","year":"1999","unstructured":"Sathasivam K, Hobbs C, Turmaine M et al (1999) Formation of polyglutamine inclusions in non-CNS tissue. Hum Mol Genet 8:813\u2013822. https:\/\/doi.org\/10.1093\/hmg\/8.5.813","journal-title":"Hum Mol Genet"},{"key":"844_CR138","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3233\/JHD-120044","volume":"2","author":"SJ Sch\u00f6nberger","year":"2013","unstructured":"Sch\u00f6nberger SJ, Jezdic D, Faull RLM, Cooper GJS (2013) Proteomic analysis of the human brain in Huntington\u2019s disease indicates pathogenesis by molecular processes linked to other neurodegenerative diseases and to type-2 diabetes. J Huntingtons Dis 2:89\u201399. https:\/\/doi.org\/10.3233\/JHD-120044","journal-title":"J Huntingtons Dis"},{"key":"844_CR139","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147269","volume":"11","author":"AM Schroeder","year":"2016","unstructured":"Schroeder AM, Wang HB, Park S et al (2016) Cardiac dysfunction in the BACHD mouse model of Huntington\u2019s disease. PLoS ONE 11:e0147269. https:\/\/doi.org\/10.1371\/journal.pone.0147269","journal-title":"PLoS ONE"},{"key":"844_CR140","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/BF01851645","volume":"167","author":"R Schubotz","year":"1976","unstructured":"Schubotz R, Hausmann L, Kaffarnik H et al (1976) Fatty acid patterns and glucose tolerance in Huntington\u2019s chorea (author\u2019s transl). Res Exp Med 167:203\u2013215. https:\/\/doi.org\/10.1007\/BF01851645","journal-title":"Res Exp Med"},{"key":"844_CR141","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.parkreldis.2016.10.017","volume":"34","author":"S Sciacca","year":"2017","unstructured":"Sciacca S, Favellato M, Madonna M et al (2017) Early enteric neuron dysfunction in mouse and human Huntington disease. Parkinsonism Relat Disord 34:73\u201374. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.10.017","journal-title":"Parkinsonism Relat Disord"},{"key":"844_CR142","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1001\/archneur.56.10.1248","volume":"56","author":"KR Sharma","year":"1999","unstructured":"Sharma KR, Romano JG, Ayyar DR et al (1999) Sympathetic skin response and heart rate variability in patients with Huntington disease. Arch Neurol 56:1248\u20131252. https:\/\/doi.org\/10.1001\/archneur.56.10.1248","journal-title":"Arch Neurol"},{"key":"844_CR143","doi-asserted-by":"publisher","first-page":"E49","DOI":"10.1152\/ajpendo.00630.2010","volume":"301","author":"P She","year":"2011","unstructured":"She P, Zhang Z, Marchionini D et al (2011) Molecular characterization of skeletal muscle atrophy in the R6\/2 mouse model of Huntington\u2019s disease. Am J Physiol Endocrinol Metab 301:E49-61. https:\/\/doi.org\/10.1152\/ajpendo.00630.2010","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"844_CR144","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3988\/jcn.2013.9.1.21","volume":"9","author":"H Shin","year":"2013","unstructured":"Shin H, Kim MH, Lee SJ et al (2013) Decreased metabolism in the cerebral cortex in early-stage Huntington\u2019s disease: a possible biomarker of disease progression? J Clin Neurol 9:21\u201325. https:\/\/doi.org\/10.3988\/jcn.2013.9.1.21","journal-title":"J Clin Neurol"},{"key":"844_CR145","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3233\/JHD-170273","volume":"7","author":"E Silajd\u017ei\u0107","year":"2018","unstructured":"Silajd\u017ei\u0107 E, Bj\u00f6rkqvist M (2018) A critical evaluation of wet biomarkers for Huntington\u2019s disease: current status and ways forward. J Huntingtons Dis 7:109\u2013135. https:\/\/doi.org\/10.3233\/JHD-170273","journal-title":"J Huntingtons Dis"},{"key":"844_CR146","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2021.166127","volume":"1867","author":"A Singh","year":"2021","unstructured":"Singh A, Agrawal N (2021) Deciphering the key mechanisms leading to alteration of lipid metabolism in Drosophila model of Huntington\u2019s disease. Biochim Biophys Acta Mol Basis Dis 1867:166127. https:\/\/doi.org\/10.1016\/j.bbadis.2021.166127","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"844_CR147","doi-asserted-by":"publisher","first-page":"13896","DOI":"10.1038\/s41598-017-13713-5","volume":"7","author":"M Sj\u00f6gren","year":"2017","unstructured":"Sj\u00f6gren M, Duarte AI, McCourt AC et al (2017) Ghrelin rescues skeletal muscle catabolic profile in the R6\/2 mouse model of Huntington\u2019s disease. Sci Rep 7:13896. https:\/\/doi.org\/10.1038\/s41598-017-13713-5","journal-title":"Sci Rep"},{"key":"844_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104560","volume":"132","author":"M Sj\u00f6gren","year":"2019","unstructured":"Sj\u00f6gren M, Soylu-Kucharz R, Dandunna U et al (2019) Leptin deficiency reverses high metabolic state and weight loss without affecting central pathology in the R6\/2 mouse model of Huntington\u2019s disease. Neurobiol Dis 132:104560. https:\/\/doi.org\/10.1016\/j.nbd.2019.104560","journal-title":"Neurobiol Dis"},{"key":"844_CR149","doi-asserted-by":"publisher","first-page":"43030","DOI":"10.1038\/srep43030","volume":"7","author":"DJ Skene","year":"2017","unstructured":"Skene DJ, Middleton B, Fraser CK et al (2017) Metabolic profiling of presymptomatic Huntington\u2019s disease sheep reveals novel biomarkers. Sci Rep 7:43030. https:\/\/doi.org\/10.1038\/srep43030","journal-title":"Sci Rep"},{"key":"844_CR150","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1016\/j.celrep.2018.04.052","volume":"23","author":"NH Skotte","year":"2018","unstructured":"Skotte NH, Andersen JV, Santos A et al (2018) Integrative characterization of the R6\/2 mouse model of Huntington\u2019s disease reveals dysfunctional astrocyte metabolism. Cell Rep 23:2211\u20132224. https:\/\/doi.org\/10.1016\/j.celrep.2018.04.052","journal-title":"Cell Rep"},{"key":"844_CR151","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/35099568","volume":"413","author":"JS Steffan","year":"2001","unstructured":"Steffan JS, Bodai L, Pallos J et al (2001) Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413:739\u2013743. https:\/\/doi.org\/10.1038\/35099568","journal-title":"Nature"},{"key":"844_CR152","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41591-018-0119-2","volume":"24","author":"H Stower","year":"2018","unstructured":"Stower H (2018) A pig model of Huntington\u2019s disease. Nat Med 24:898. https:\/\/doi.org\/10.1038\/s41591-018-0119-2","journal-title":"Nat Med"},{"key":"844_CR153","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1093\/hmg\/ddi192","volume":"14","author":"AD Strand","year":"2005","unstructured":"Strand AD, Aragaki AK, Shaw D et al (2005) Gene expression in Huntington\u2019s disease skeletal muscle: a potential biomarker. Hum Mol Genet 14:1863\u20131876. https:\/\/doi.org\/10.1093\/hmg\/ddi192","journal-title":"Hum Mol Genet"},{"key":"844_CR154","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1212\/WNL.0b013e318282514e","volume":"80","author":"SH St\u00fcwe","year":"2013","unstructured":"St\u00fcwe SH, Goetze O, Lukas C et al (2013) Hepatic mitochondrial dysfunction in manifest and premanifest Huntington disease. Neurology 80:743\u2013746. https:\/\/doi.org\/10.1212\/WNL.0b013e318282514e","journal-title":"Neurology"},{"key":"844_CR155","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0168-9525(03)00074-X","volume":"19","author":"KL Sugars","year":"2003","unstructured":"Sugars KL, Rubinsztein DC (2003) Transcriptional abnormalities in Huntington disease. Trends Genet 19:233\u2013238. https:\/\/doi.org\/10.1016\/S0168-9525(03)00074-X","journal-title":"Trends Genet"},{"issue":"6","key":"844_CR156","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s00415-015-7753-0","volume":"262","author":"SD S\u00fcssmuth","year":"2015","unstructured":"S\u00fcssmuth SD, M\u00fcller VM, Geitner C, Landwehrmeyer GB, Iff S, Gemperli A, Orth M (2015) Fatfree mass and its predictors in Huntington\u2019s disease. J Neurol 262(6):1533\u20131540. https:\/\/doi.org\/10.1007\/s00415-015-7753-0","journal-title":"J Neurol"},{"key":"844_CR157","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/1531-8249(199901)45:1<25::AID-ART6>3.0.CO;2-E","volume":"45","author":"SJ Tabrizi","year":"1999","unstructured":"Tabrizi SJ, Cleeter MW, Xuereb J et al (1999) Biochemical abnormalities and excitotoxicity in Huntington\u2019s disease brain. Ann Neurol 45:25\u201332","journal-title":"Ann Neurol"},{"key":"844_CR158","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/1531-8249(200001)47:1<80::AID-ANA13>3.0.CO;2-K","volume":"47","author":"SJ Tabrizi","year":"2000","unstructured":"Tabrizi SJ, Workman J, Hart PE et al (2000) Mitochondrial dysfunction and free radical damage in the Huntington R6\/2 transgenic mouse. Ann Neurol 47:80\u201386","journal-title":"Ann Neurol"},{"key":"844_CR159","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1474-4422(10)70276-3","volume":"10","author":"SJ Tabrizi","year":"2011","unstructured":"Tabrizi SJ, Scahill RI, Durr A et al (2011) Biological and clinical changes in premanifest and early stage Huntington\u2019s disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 10:31\u201342. https:\/\/doi.org\/10.1016\/S1474-4422(10)70276-3","journal-title":"Lancet Neurol"},{"key":"844_CR160","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(11)70263-0","volume":"11","author":"SJ Tabrizi","year":"2012","unstructured":"Tabrizi SJ, Reilmann R, Roos RAC et al (2012) Potential endpoints for clinical trials in premanifest and early Huntington\u2019s disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 11:42\u201353. https:\/\/doi.org\/10.1016\/S1474-4422(11)70263-0","journal-title":"Lancet Neurol"},{"key":"844_CR161","doi-asserted-by":"publisher","first-page":"7899","DOI":"10.1523\/JNEUROSCI.1396-07.2007","volume":"27","author":"T-S Tang","year":"2007","unstructured":"Tang T-S, Chen X, Liu J, Bezprozvanny I (2007) Dopaminergic signaling and striatal neurodegeneration in Huntington\u2019s disease. J Neurosci 27:7899\u20137910. https:\/\/doi.org\/10.1523\/JNEUROSCI.1396-07.2007","journal-title":"J Neurosci"},{"key":"844_CR162","doi-asserted-by":"publisher","first-page":"4076","DOI":"10.1172\/JCI69411","volume":"123","author":"CC Tang","year":"2013","unstructured":"Tang CC, Feigin A, Ma Y et al (2013) Metabolic network as a progression biomarker of premanifest Huntington\u2019s disease. J Clin Investig 123:4076\u20134088. https:\/\/doi.org\/10.1172\/JCI69411","journal-title":"J Clin Investig"},{"key":"844_CR163","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1080\/15257770.2016.1154969","volume":"35","author":"M Toczek","year":"2016","unstructured":"Toczek M, Kutryb-Zajac B, Zukowska P et al (2016) Changes in cardiac nucleotide metabolism in Huntington\u2019s disease. Nucleosides Nucleotides Nucleic Acids 35:707\u2013712. https:\/\/doi.org\/10.1080\/15257770.2016.1154969","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"844_CR164","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.nut.2003.10.007","volume":"20","author":"A Trejo","year":"2004","unstructured":"Trejo A, Tarrats RM, Alonso ME et al (2004) Assessment of the nutrition status of patients with Huntington\u2019s disease. Nutrition 20:192\u2013196. https:\/\/doi.org\/10.1016\/j.nut.2003.10.007","journal-title":"Nutrition"},{"key":"844_CR165","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1002\/mds.21540","volume":"22","author":"C Turner","year":"2007","unstructured":"Turner C, Cooper JM, Schapira AHV (2007) Clinical correlates of mitochondrial function in Huntington\u2019s disease muscle. Mov Disord 22:1715\u20131721. https:\/\/doi.org\/10.1002\/mds.21540","journal-title":"Mov Disord"},{"key":"844_CR166","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S1474-4422(09)70178-4","volume":"8","author":"JMM van der Burg","year":"2009","unstructured":"van der Burg JMM, Bj\u00f6rkqvist M, Brundin P (2009) Beyond the brain: widespread pathology in Huntington\u2019s disease. Lancet Neurol 8:765\u2013774. https:\/\/doi.org\/10.1016\/S1474-4422(09)70178-4","journal-title":"Lancet Neurol"},{"key":"844_CR167","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2011.05.006","volume":"44","author":"JMM van der Burg","year":"2011","unstructured":"van der Burg JMM, Winqvist A, Aziz NA et al (2011) Gastrointestinal dysfunction contributes to weight loss in Huntington\u2019s disease mice. Neurobiol Dis 44:1\u20138. https:\/\/doi.org\/10.1016\/j.nbd.2011.05.006","journal-title":"Neurobiol Dis"},{"key":"844_CR168","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/ana.25007","volume":"82","author":"JMM van der Burg","year":"2017","unstructured":"van der Burg JMM, Gardiner SL, Ludolph AC et al (2017) Body weight is a robust predictor of clinical progression in Huntington disease. Ann Neurol 82:479\u2013483. https:\/\/doi.org\/10.1002\/ana.25007","journal-title":"Ann Neurol"},{"key":"844_CR169","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3389\/fphys.2014.00231","volume":"5","author":"R Wang","year":"2014","unstructured":"Wang R, Ross CA, Cai H et al (2014) Metabolic and hormonal signatures in pre-manifest and manifest Huntington\u2019s disease patients. Front Physiol 5:231. https:\/\/doi.org\/10.3389\/fphys.2014.00231","journal-title":"Front Physiol"},{"key":"844_CR170","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1093\/braincomms\/fcaa110","volume":"2","author":"CI Wasser","year":"2020","unstructured":"Wasser CI, Mercieca E-C, Kong G et al (2020) Gut dysbiosis in Huntington\u2019s disease: associations among gut microbiota, cognitive performance and clinical outcomes. Brain Commun 2:110. https:\/\/doi.org\/10.1093\/braincomms\/fcaa110","journal-title":"Brain Commun"},{"key":"844_CR171","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(11)70070-9","volume":"10","author":"DW Weir","year":"2011","unstructured":"Weir DW, Sturrock A, Leavitt BR (2011) Development of biomarkers for Huntington\u2019s disease. Lancet Neurol 10:573\u2013590. https:\/\/doi.org\/10.1016\/S1474-4422(11)70070-9","journal-title":"Lancet Neurol"},{"key":"844_CR172","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.cmet.2006.10.004","volume":"4","author":"P Weydt","year":"2006","unstructured":"Weydt P, Pineda VV, Torrence AE et al (2006) Thermoregulatory and metabolic defects in Huntington\u2019s disease transgenic mice implicate PGC-1alpha in Huntington\u2019s disease neurodegeneration. Cell Metab 4:349\u2013362. https:\/\/doi.org\/10.1016\/j.cmet.2006.10.004","journal-title":"Cell Metab"},{"key":"844_CR173","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.brainresbull.2007.12.007","volume":"76","author":"NI Wood","year":"2008","unstructured":"Wood NI, Goodman AOG, van der Burg JMM et al (2008) Increased thirst and drinking in Huntington\u2019s disease and the R6\/2 mouse. Brain Res Bull 76:70\u201379. https:\/\/doi.org\/10.1016\/j.brainresbull.2007.12.007","journal-title":"Brain Res Bull"},{"key":"844_CR174","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/ana.410200305","volume":"20","author":"AB Young","year":"1986","unstructured":"Young AB, Penney JB, Starosta-Rubinstein S et al (1986) PET scan investigations of Huntington\u2019s disease: cerebral metabolic correlates of neurological features and functional decline. Ann Neurol 20:296\u2013303. https:\/\/doi.org\/10.1002\/ana.410200305","journal-title":"Ann Neurol"},{"key":"844_CR175","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3389\/fphys.2014.00380","volume":"5","author":"D Zielonka","year":"2014","unstructured":"Zielonka D, Piotrowska I, Marcinkowski JT, Mielcarek M (2014) Skeletal muscle pathology in Huntington\u2019s disease. Front Physiol 5:380. https:\/\/doi.org\/10.3389\/fphys.2014.00380","journal-title":"Front Physiol"},{"key":"844_CR176","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3389\/fmed.2020.00079","volume":"7","author":"D Zielonka","year":"2020","unstructured":"Zielonka D, Witkowski G, Puch EA et al (2020) Prevalence of non-psychiatric comorbidities in pre-symptomatic and symptomatic Huntington\u2019s disease gene carriers in Poland. Front Med 7:79. https:\/\/doi.org\/10.3389\/fmed.2020.00079","journal-title":"Front Med"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-021-00844-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11011-021-00844-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-021-00844-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T17:22:31Z","timestamp":1657819351000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11011-021-00844-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":176,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["844"],"URL":"https:\/\/doi.org\/10.1007\/s11011-021-00844-y","relation":{},"ISSN":["0885-7490","1573-7365"],"issn-type":[{"value":"0885-7490","type":"print"},{"value":"1573-7365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,27]]},"assertion":[{"value":"11 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}